Kinnate Biopharma Inc (NASDAQ:KNTE) announced pipeline updates, a reprioritization plan, and workforce restructuring to extend the cash runway. The company is prioritizing the exarafenib combination, KIN-8741, and discovery efforts around its CDK4 selective program. Kinnate will pause the development of KIN-7136 and explore strategic alternatives for exarafenib monotherapy and KIN-3248. The company will also reduce its workforce by approximately 70% and take measures to reduce operating expenses. As of June 30, 2023, Kinnate had approximately $204.3 million in cash, cash equivalents and investments.